Abstract:Objective The aim of this study was to characterize the population frequency of SLCO1B1 polymorphic variants in three distinct healthy Asian populations, namely Chinese (n=100), Malay (n=100) and Indian (n=100), and to explore the association between haplotype-tagged single nucleotide polymorphisms (htSNPs) on hepatic SLCO1B1 mRNA expression.Methods The distribution of polymorphic variants in the SLCO1B1 gene at eight loci that spanned approximately 48 kb was investigated in the three different Asian ethnic groups and in 32 non-cancerous liver tissues from Chinese patients.Results Of the 26 polymorphisms screened, we found eight polymorphic variants that differed in genotypic and allelic frequencies between the Chinese, Malay and Indian populations. Significant interethnic differences were observed in the genotype frequency distributions across the promoter SNP [g.-11187G > A (P=0.030)] as well as three coding region SNPs [c.388G > A (P < 0.001); c.571T > C (P < 0.001); c.597C > T (P < 0.001)] in the healthy subjects. Haplotype analysis revealed 12 different haplotypes in both the Chinese and Malay populations and 18 haplotypes in the Indian population. In both the Malay and Indian populations, the htSNPs were c.388A > G, c.571T > C and c.597C > T, whereas in the Chinese population they were g.-11187G > A, c.388A > G and c.597C > T. The c.388A > G and c.597C > T htSNPs accounted for more than 70% of the variations between the three major haplotypes in each Asian ethnic group. In terms of the c.388A > G htSNPs, genotypic-phenotypic association analyses revealed that there was no effect on SLCO1B1 expression in hepatic tissues; in addition, no genotypic-phenotypic associations were evident with regards to the c.597C > T htSNP.Conclusion Future studies should investigate the phenotypic effects of the c.388A > G htSNP on the disposition of OATP1B1 substrates in Asian populations.

Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.

Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis

The Influence of MDR1 G2677T/A Genetic Polymorphisms on the Pharmacokinetics of Repaglinide in Healthy Chinese Volunteers

Drug–drug Interaction of Rabeprazole and Clopidogrel in Healthy Chinese Volunteers

Gene Polymorphisms of Insulin Secretion Signaling Pathway Associated with Clopidogrel Resistance in Han Chinese Population.

Relationship Between the Genetic Variants in SLCOI B1 Gene and the Response to Repaglinide Treatment in Newly-Diagnosed Type 2 Diabetic Patients

Influence of the SLCO1B3 Gene on Sulfonylurea Failure in Patients with Type 2 Diabetes in China.

Effects of Functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 Genetic Variants on the Pharmacokinetics of Insulin Sensitizer Pioglitazone in Chinese Han Individuals

A Variation in NOS1AP Gene is Associated with Repaglinide Efficacy on Insulin Resistance in Type 2 Diabetes of Chinese

Association of<i>KCNJ11</i>and<i>ABCC8</i>genetic polymorphisms with response to repaglinide in Chinese diabetic patients<sup>1</sup>

Effects Of Kcnq1 Polymorphisms On The Therapeutic Efficacy Of Oral Antidiabetic Drugs In Chinese Type 2 Diabetes Patients

Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

In vitro and in vivo drug-drug interaction of losartan and glimepiride in rats and its possible mechanism.

CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.

Polymorphism Of Orm1 Is Associated With The Pharmacokinetics Of Telmisartan

The association of SLC22A1 rs628031 polymorphism with the adverse reaction of metformin

Association Ofkcnj11andabcc8genetic Polymorphisms with Response to Repaglinide in Chinese Diabetic Patients1

Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia

CYP2C9 Ile359Leu Polymorphism, Plasma Irbesartan Concentration and Acute Blood Pressure Reductions in Response to Irbesartan Treatment in Chinese Hypertensive Patients.

Pharmacogenetics of SLCO1B1: Haplotypes, Htsnps and Hepatic Expression in Three Distinct Asian Populations